PRF Technologies (PRFX) Short-term Investments (2022 - 2025)
PRF Technologies (PRFX) posted quarterly Short-term Investments of $1.0 million for Q4 2025, little changed on a QoQ basis from $1.0 million in Q2 2023.
PRF Technologies (PRFX) Short-term Investments (2022 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Short-term Investments for 3 consecutive years, with $1.0 million the latest figure, recorded in Q4 2025.
- Quarterly Short-term Investments changed N/A year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.0 million, changed N/A from the prior year.
- Short-term Investments held at $1.0 million in Q4 2025 per PRFX's latest filing, from $1.0 million in the prior quarter.
- Over the last five years, Short-term Investments for PRFX reached as high as $6.1 million in Q4 2022 and fell as low as $1.0 million in Q2 2023.
- A 3-year average of $3.5 million and a median of $3.5 million in 2022 frame the typical range for Short-term Investments.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.02 Mn |
| Jun 30, 2023 | 1.01 Mn |
| Dec 31, 2022 | 6.09 Mn |
| Sep 30, 2022 | 6.03 Mn |